(1) Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68, 394–424 (2018).
(2) Planchard, D. et al. Correction to: ‘Metastatic non-small cell lung cancer: ESMO Clinical Practic Guidelines for diagnosis, treatment and follow-up’. Ann Oncol 30, 863–870 (2019).
(3) Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. .J Clin Oncol. 2018 Jun 10;36(17):1675-1684. doi: 10.1200/JCO.2017.77.0412.
(4) Reck, M. et al. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 37, 537–546 (2019).)
(5) Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, et al. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136.
(6) Paz-Ares L, Vicente D, Tafreshi A, Robinson A, Soto Parra H, Mazières J, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407.J Thorac Oncol. 2020 Oct;15(10):1657-1669. doi: 10.1016/j
(7) Pai-Scherf L, Blumenthal GM, Li H, Subramaniam S, Mishra-Kalyani PS, He K, Zhao H, et al. FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. Oncologist. 2017 Nov;22(11):1392-1399. doi: 10.1634/theoncologist.
(8) Reck M, Schenker M, Lee KH, Provencio M, Nishio M, Lesniewski-Kmak K, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur J Cancer. 2019 Jul;116:137-147. doi: 10.1016/j.ejca.2019.05.008.
(9) Petitprez, F., Meylan, M., de Reyniès, A., Sautès-Fridman, C. & Fridman, W. H. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Front. Immunol. 11, (2020).
(10) Fortunato, O. et al. Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk. Int J Cancer 144, 2746–2761 (2019).
(11) Prelaj, A. et al. Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer. Eur J Cancer 106, 144–159 (2019).
(12) Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–9 (2015).
(13) Yoon, H. J. et al. Deciphering the tumor microenvironment through radiomics in non-small cell lung cancer: Correlation with immune profiles. PloS One 15, e0231227 (2020).
(14) Prelaj, A. et al. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non– Small-cell Lung Cancer Treated With Immunotherapy. Clin. Lung Cancer 0, (2020).
(15) Sorich, M. J., Rowland, A., Karapetis, C. S. & Hopkins, A. M. Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical Trials. J. Thorac. Oncol. 1440–1446 (2019).
(16) Triberti, S., Durosini, I. & Pravettoni, G. A “Third Wheel” Effect in Health Decision Making Involving Artificial Entities: A Psychological Perspective. Front. Public Health 8, (2020).
(17) Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosisof computed tomography detected lung cancer. Proc Natl Acad Sci U S A 2011;108:3713-8.
(18) (Sozzi G, Boeri M, Rossi M, et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study. J Clin Oncol 2014;32:768-73.
(19) Boeri M, Milione M, Proto C, Signorelli D, Lo Russo G, Carlotta Galeone C. et al. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019 Apr 1;25(7):2166-2173
(20) Prelaj A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Mensah M, et al. Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system. Transl Lung Cancer Res. 2020 Jun;9(3):617-628. doi: 10.21037/tlcr-20-231.
(21) Mensah M, Borzi C, Verri C, et al. MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening. J Vis Exp 2017;(128):56326.
(22) Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.
(23) Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, et al. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 Feb 1;25(3):989-999. doi: 10.1158/1078-0432.CCR-18-1390.
24 (26) B. He et al., “Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker,” J. Immunother. Cancer, vol. 8, no. 2, pp. 1–10, 2020, doi: 10.1136/jitc-2020-000550.
(25) M. Khorrami, P. Prasanna, A. Gupta, P. Patil, P. D. Velu, R. Thawani, et al. Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer. Cancer Immunol Res , 8(1):108{119, 01 2020.April 26,
(26) Y. Yang, J. Yang, L. Shen, J. Chen, L. Xia, B. Ni, L. Ge, et al. A multi-omics-based serial deep learning approach to predict clinical outcomes of single-agent anti-PD-1/PD-L1 immunotherapy in advanced stage non-small-cell lung cancer. Am J Transl Res , 13(2):743{756, 2021.
(27) Chao Fang Ch, Dong Xu D, Jing Su J, Jonathan R Dry JR & Bolan Linghu B. DeePaN: deep patient graph convolutional network integrating clinico-genomic evidence to stratify lung cancers for immunotherapy. npj Digital Medicine volume 4, Article number: 14 (2021)
(28) Tian P, He B, Mu W, Kunqin Liu K, Liu L, Zeng H et al. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. Theranostics. 2021; 11(5): 2098–2107. doi: 10.7150/thno.4802
(29) L. Xue, G. Bi, C. Zhan, Y. Zhang, Y. Yuan, and H. Fan, “Development and Validation of a 12-Gene Immune Relevant Prognostic Signature for Lung Adenocarcinoma Through Machine Learning Strategies,” Front. Oncol., vol. 10, no. May, pp. 1–14, 2020, doi: 10.3389/fonc.2020.00835.
(30) Y. H. Lai, W. N. Chen, T. C. Hsu, C. Lin, Y. Tsao, and S. Wu, “Overall survival prediction of non-small cell lung cancer by integrating microarray and clinical data with deep learning,” Sci. Rep., vol. 10, no. 1, pp. 1–11, 2020, doi: 10.1038/s41598-020-61588-w
(31) J. A. Bartholomai and H. B. Frieboes. Lung Cancer Survival Prediction via Machine Learning Regression Classification, and Statistical Techniques. Proc IEEE Int Symp Signal Proc Inf Tech , 2018:632{637, Dec 2018.
(32) Johannet P, Coudray N, Donnelly DM, Jour G, Illa-Bochaca I, Xia Y et al. Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma Clin Cancer Res. 2021 Jan 1;27(1):131-140. doi: 10.1158/1078-0432.CCR-20-2415.
(33) Z. Lu et al., “Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier,” J. Immunother. Cancer, vol. 8, no. 2, pp. 1–5, 2020, doi: 10.1136/jitc-2020-000631.
(34) F. Rundo, C. Spampinato, G. L. Banna, and S. Conoci, “Advanced deep learning embedded motion radiomics pipeline for predicting anti-PD-1/PD-L1 immunotherapy response in the treatment of bladder cancer: Preliminary results,” Electron., vol. 8, no. 10, 2019, doi: 10.3390/electronics8101134.